? Breast cancer is a difficult disease to manage because it is comprised of a wide spectrum of tumor subtypes with different biological characteristics, therapeutic responses and clinical outcomes. A biomarker-based classification of breast cancer that effectively matches intrinsic biological characteristics with the most effective therapeutic protocol would be a significant advance. Gene expression analysis using a breast tumor """"""""intrinsic"""""""" gene set has reproducibly identified five distinct subtypes of breast tumors: Luminal A (LumA), Luminal B (LumB), Normal Breast-like (NB), HER2-positive (HER2+) and Basal-like. Each subtype has a distinct biology and clinical behavior and evidence suggests that each has a unique drug sensitivity pattern. We have also shown that this classification identifies prognostic groups that are reproducible across different patient populations and are independent of standard clinical parameters. RNA expression profiling is the most robust and reproducible way to identify these biological subtypes and we believe that our proposed classification can be accomplished in an automated fashion without subjective interpretation. In order to generalize the clinical significance of these findings to larger populations we will develop an assay to allow classification from formalin-fixed, paraffin-embedded (FFPE) tissues so that RNA from aged blocks can be accurately profiled. Next, we will retrospectively validate our """"""""intrinsic"""""""" gene set on uniformly treated cohorts of thousands of patients. Our goal is to develop a clinical test for these five subtypes using expression analysis by real-time quantitative RT-PCR. With the additional information that we expect to gain by profiling clinical samples from homogeneously treated patients and patients subjected to treatment randomization, we will be able to provide valuable prognostic information for patients with node negative breast cancer and predictive information for the efficacy of chemotherapy regimens for patients with node positive disease. It is our long term goal to develop a broadly applicable subtyping test for all early stage breast cancer patients. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA114722-03
Application #
7273500
Study Section
Special Emphasis Panel (ZCA1-SRRB-4 (J1))
Program Officer
Lively, Tracy (LUGO)
Project Start
2005-09-29
Project End
2010-05-31
Budget Start
2007-06-01
Budget End
2008-05-31
Support Year
3
Fiscal Year
2007
Total Cost
$1,549,377
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Asleh, Karama; Won, Jennifer R; Gao, Dongxia et al. (2018) Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up. Breast Cancer Res Treat 168:107-115
Ellis, Matthew J; Suman, Vera J; Hoog, Jeremy et al. (2017) Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol 35:1061-1069
Luo, Jingqin; Liu, Shuzhen; Leung, Samuel et al. (2017) An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors. J Mol Diagn 19:147-161
Liu, Minetta C; Pitcher, Brandelyn N; Mardis, Elaine R et al. (2016) PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ Breast Cancer 2:
Miller, Christopher A; Gindin, Yevgeniy; Lu, Charles et al. (2016) Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun 7:12498
Wallden, Brett; Storhoff, James; Nielsen, Torsten et al. (2015) Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genomics 8:54
Cheang, Maggie C U; Martin, Miguel; Nielsen, Torsten O et al. (2015) Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist 20:474-82
Ligibel, Jennifer A; Cirrincione, Constance T; Liu, Minetta et al. (2015) Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst 107:
Liu, Shuzhen; Foulkes, William D; Leung, Samuel et al. (2014) Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res 16:432
Prat, A; Lluch, A; Albanell, J et al. (2014) Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer 111:1532-41

Showing the most recent 10 out of 33 publications